These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

961 related items for PubMed ID: 27920336

  • 41. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT, Changolkar AK, Scott McKenzie R.
    J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study.
    Balsa A, Sanmarti R, Rosas J, Martin V, Cabez A, Gómez S, Montoro M.
    Rheumatology (Oxford); 2018 Apr 01; 57(4):688-693. PubMed ID: 29365183
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
    Finckh A, Simard JF, Gabay C, Guerne PA, SCQM physicians.
    Ann Rheum Dis; 2006 Jun 01; 65(6):746-52. PubMed ID: 16339288
    [Abstract] [Full Text] [Related]

  • 50. [Etanercept--infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFalpha].
    Brocq O, Plubel Y, Breuil V, Grisot C, Flory P, Mousnier A, Euller-Ziegler L.
    Presse Med; 2002 Nov 23; 31(39 Pt 1):1836-9. PubMed ID: 12496713
    [Abstract] [Full Text] [Related]

  • 51. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors.
    Iannone F, Gremese E, Atzeni F, Biasi D, Botsios C, Cipriani P, Ferri C, Foschi V, Galeazzi M, Gerli R, Giardina A, Marchesoni A, Salaffi F, Ziglioli T, Lapadula G, Gruppo Italiano di Studio sulle Early Arthritides (GISEA).
    J Rheumatol; 2012 Jun 23; 39(6):1179-84. PubMed ID: 22467933
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.
    Int J Rheum Dis; 2012 Jun 23; 15(3):330-5. PubMed ID: 22709496
    [Abstract] [Full Text] [Related]

  • 54. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L, Pope JE, Payne M.
    J Rheumatol; 2009 Jul 23; 36(7):1421-8. PubMed ID: 19487267
    [Abstract] [Full Text] [Related]

  • 55. Reduction of biological agent dose in rheumatic diseases: descriptive analysis of 153 patients in clinical practice conditions.
    Inciarte-Mundo J, Hernández MV, Rosario V, Ruiz-Esquide V, Cabrera-Villalba S, Ramírez J, Cañete JD, Sanmartí R.
    Reumatol Clin; 2014 Jul 23; 10(1):10-6. PubMed ID: 23876791
    [Abstract] [Full Text] [Related]

  • 56. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
    Bombardieri S, Ferraccioli G, Ferri C, Galeazzi M, Lapadula G, Cerinic MM, Montecucco C, Triolo G, Trotta F, Valentini G.
    Reumatismo; 2009 Jul 23; 61 Suppl 1():1-23. PubMed ID: 19999184
    [Abstract] [Full Text] [Related]

  • 57. Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons leading to discontinuation of the treatment.
    Levälampi T, Korpela M, Vuolteenaho K, Moilanen E.
    Rheumatol Int; 2008 Jan 23; 28(3):261-9. PubMed ID: 17846778
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 49.